Vaccine problems, plans scrutinized during Senate hearing

Facing criticism for wasting hundreds of millions of dollars on anthrax vaccines, a top Health and Human Services official said Tuesday that the agency needs more money to prevent similar problems.

A Government Accountability Office report released Tuesday detailed HHS missteps, including losing tens of millions of dollars on expiring vaccines and awarding a $877 million contract that the agency canceled after an unproven pharmaceutical company called VaxGen failed to meet what HHS acknowledges were unrealistic expectations for a new vaccine.

The report drew rebukes at a Senate Homeland Security and Governmental Affairs hearing on bioterrorism preparation, held to coincide with the sixth anniversary of anthrax attacks that killed six people in 2001.

"The Department of Health and Human Services' efforts to develop a second generation anthrax vaccine -- to improve upon the 30-year-old-technology we have in the stockpile -- has, in a word, failed," Senate Homeland Security and Governmental Affairs Chairman Joseph Lieberman, I-Conn., said in an opening statement. "This is a disappointing failure that has put us back at square one after years of work."

Gerald Parker, principal deputy assistant secretary in HHS' office of the assistant secretary for preparedness and response, observed that anthrax vaccines are only one piece of efforts by HHS and the Homeland Security Department to prepare for biological threats through their $5.6 billion BioShield project.

Recognizing that it had been contracting too early in the risky drug development process, the agency is working to buy vaccines that are "further down the pipeline," Parker said.

For commercial markets, drug makers often raise capital to pay for development costs. But with no private market for biodefense products, big pharmaceutical companies have not competed for contracts to sell vaccines to the government, causing agencies to rely on smaller, less risk-averse companies.

According to GAO, established drug-makers have also stayed away because a lack of clear requirements from government departments places additional risks on contractors. Lieberman agreed with those sentiments. "We have to find a way to entice the big pharmaceutical companies to get into this," he said.

Parker said $189 million in the president's fiscal 2008 budget request for advanced drug development will spur needed research. The Biodefense and Pandemic Vaccine and Drug Development Act of 2006 calls for advanced biodefense research, but Congress thus far has not funded the so-called BARDA Act.

Tara O'Toole, director of the Center for Biosecurity at the University of Pittsburgh Medical Center, said the gap between the government's goals for guarding against biological terrorism and its spending is much larger than most involved realize. "Five billion [dollars] is much less than we're going to need," O'Toole said.

Stay up-to-date with federal news alerts and analysis — Sign up for GovExec's email newsletters.
FROM OUR SPONSORS
JOIN THE DISCUSSION
Close [ x ] More from GovExec
 
 

Thank you for subscribing to newsletters from GovExec.com.
We think these reports might interest you:

  • Going Agile:Revolutionizing Federal Digital Services Delivery

    Here’s one indication that times have changed: Harriet Tubman is going to be the next face of the twenty dollar bill. Another sign of change? The way in which the federal government arrived at that decision.

    View
  • Cyber Risk Report: Cybercrime Trends from 2016

    In our first half 2016 cyber trends report, SurfWatch Labs threat intelligence analysts noted one key theme – the interconnected nature of cybercrime – and the second half of the year saw organizations continuing to struggle with that reality. The number of potential cyber threats, the pool of already compromised information, and the ease of finding increasingly sophisticated cybercriminal tools continued to snowball throughout the year.

    View
  • Featured Content from RSA Conference: Dissed by NIST

    Learn more about the latest draft of the U.S. National Institute of Standards and Technology guidance document on authentication and lifecycle management.

    View
  • GBC Issue Brief: The Future of 9-1-1

    A Look Into the Next Generation of Emergency Services

    View
  • GBC Survey Report: Securing the Perimeters

    A candid survey on cybersecurity in state and local governments

    View
  • The New IP: Moving Government Agencies Toward the Network of The Future

    Federal IT managers are looking to modernize legacy network infrastructures that are taxed by growing demands from mobile devices, video, vast amounts of data, and more. This issue brief discusses the federal government network landscape, as well as market, financial force drivers for network modernization.

    View
  • eBook: State & Local Cybersecurity

    CenturyLink is committed to helping state and local governments meet their cybersecurity challenges. Towards that end, CenturyLink commissioned a study from the Government Business Council that looked at the perceptions, attitudes and experiences of state and local leaders around the cybersecurity issue. The results were surprising in a number of ways. Learn more about their findings and the ways in which state and local governments can combat cybersecurity threats with this eBook.

    View

When you download a report, your information may be shared with the underwriters of that document.